Impact of COVID-19 Lockdown on Glycemic Control in Patients with Type 1 Diabetes

Overview

Journal Diabetes Res Clin Pract

Specialty Endocrinology

Date 2020 Jul 26

PMID 32711000

Citations 75

Authors

Elsa Fernandez

Alicia Cortazar

Virginia Bellido

Affiliations

Soon will be listed here.

Abstract

Introduction: The COVID-19 pandemic has forced governments to take exceptional measures to minimize its spread, imposing lockdown policies. The aim of this study was to evaluate the impact of lockdown on type 1 diabetes (T1D) glycemic control.

Material And Methods: People with T1D using flash glucose monitoring were included. Data from the 14 days before lockdown were compared with data from the last 14 days after 8 weeks of lockdown.

Results: A total of 307 patients were included (age 45.8 ± 12.6 years, 50.2% male, diabetes duration 21.1 ± 12.3 years). Only one patient had COVID-19 infection. Mean glucose decreased from 166.89 ± 29.4 to 158.0 ± 29.0 mg/dL and estimated HbA1c declined from 7.4 ± 1.0 to 7.1 ± 1.0% (54 ± 10.9 vs 57 ± 10.9 mmol/mol; p < 0.001). Time in range increased from 57.8 ± 15.8 to 62.46 ± 16.1%. Time in hyperglycemia > 180 mg/dL and >250 mg/dL decreased from 37.3 ± 1.9% to 32.0 ± 17.1% and from 13.0 ± 11.3 to 10.3 ± 10.6%, respectively; (p < 0.001). Time in hypoglycaemia <70 mg/dL increased from 4.9 ± 4.0% to 5.5 ± 4.4% (p < 0.001). No differences in time <54 mg/dl, coefficient of variation (CV%) or number of scans per day were found.

Conclusion: Despite the limitations of lockdown, glycemic control improved in patients with T1D. These results suggest that having more time for self-management may help improve glycemic control in the short term.

Citing Articles

The profound impact of COVID-19 on the control and care of diabetic patients: a comprehensive retrospective cohort study.

Al Rashdi F, Al Harrasi S, Al Ismaili M, Yaaqubi A, Atwan Z, Tabche C BMC Prim Care. 2024; 25(1):432.

PMID: 39709343 PMC: 11662608. DOI: 10.1186/s12875-024-02672-2.

Experiences and Health Outcomes of Emerging Adults With Type 1 Diabetes: A Mixed-Methods Study.

Al Bayrakdar A, Puzantian H, Noureddine S, Abu-Saad Huijer H, Nasrallah M, Joiner K Nurs Res. 2024; 74(2):98-107.

PMID: 39330873 PMC: 11895817. DOI: 10.1097/NNR.0000000000000781.

Changes in Self-Efficacy During COVID-19 Among Adolescents With Type 1 Diabetes Mellitus: A Qualitative Study.

Okonkwo N, Bergner E, Jaser S J Pediatr Health Care. 2024; 38(6):830-835.

PMID: 39306780 PMC: 11571680. DOI: 10.1016/j.pedhc.2024.07.005.

Impact of Continuous Glucose Monitoring and its Glucometrics in Clinical Practice in Spain and Future Perspectives: A Narrative Review.

Gomez-Peralta F, Leiva-Gea I, Duque N, Artime E, Rubio de Santos M Adv Ther. 2024; 41(9):3471-3488.

PMID: 39093492 PMC: 11349838. DOI: 10.1007/s12325-024-02943-5.

Effects of Two COVID-19 Lockdowns on HbA1c Levels in Patients with Type 1 Diabetes and Associations with Digital Treatment, Health Literacy, and Diabetes Self-Management: A Multicenter, Observational Cohort Study Over 3 Years.

Tajdar D, Luhmann D, Walther L, Bittner L, Scherer M, Schafer I Diabetes Ther. 2024; 15(6):1375-1388.

PMID: 38642263 PMC: 11096287. DOI: 10.1007/s13300-024-01574-x.

References

Strandberg R, Graue M, Wentzel-Larsen T, Peyrot M, B Thordarson H, Rokne B . Longitudinal relationship between diabetes-specific emotional distress and follow-up HbA1c in adults with Type 1 diabetes mellitus. Diabet Med. 2015; 32(10):1304-10. PMC: 4676291. DOI: 10.1111/dme.12781. View

Peters A, Garg S . The Silver Lining to COVID-19: Avoiding Diabetic Ketoacidosis Admissions with Telehealth. Diabetes Technol Ther. 2020; 22(6):449-453. DOI: 10.1089/dia.2020.0187. View

Saez M, Tobias A, Varga D, Barcelo M . Effectiveness of the measures to flatten the epidemic curve of COVID-19. The case of Spain. Sci Total Environ. 2020; 727:138761. PMC: 7166106. DOI: 10.1016/j.scitotenv.2020.138761. View

Sher L . COVID-19, anxiety, sleep disturbances and suicide. Sleep Med. 2020; 70:124. PMC: 7195057. DOI: 10.1016/j.sleep.2020.04.019. View

Bellido V, Perez A . Consequences of COVID-19 on people with diabetes. Endocrinol Diabetes Nutr (Engl Ed). 2020; 67(6):355-356. PMC: 7211748. DOI: 10.1016/j.endinu.2020.04.001. View

Gomez-Peralta F, Dunn T, Landuyt K, Xu Y, Merino-Torres J . Flash glucose monitoring reduces glycemic variability and hypoglycemia: real-world data from Spain. BMJ Open Diabetes Res Care. 2020; 8(1). PMC: 7103828. DOI: 10.1136/bmjdrc-2019-001052. View

Cucinotta D, Vanelli M . WHO Declares COVID-19 a Pandemic. Acta Biomed. 2020; 91(1):157-160. PMC: 7569573. DOI: 10.23750/abm.v91i1.9397. View

Ghosal S, Sinha B, Majumder M, Misra A . Estimation of effects of nationwide lockdown for containing coronavirus infection on worsening of glycosylated haemoglobin and increase in diabetes-related complications: A simulation model using multivariate regression analysis. Diabetes Metab Syndr. 2020; 14(4):319-323. PMC: 7146694. DOI: 10.1016/j.dsx.2020.03.014. View

Battelino T, Danne T, Bergenstal R, Amiel S, Beck R, Biester T . Clinical Targets for Continuous Glucose Monitoring Data Interpretation: Recommendations From the International Consensus on Time in Range. Diabetes Care. 2019; 42(8):1593-1603. PMC: 6973648. DOI: 10.2337/dci19-0028. View

10.

Reddy M, Rilstone S, Cooper P, Oliver N . Type 1 diabetes in adults: supporting self management. BMJ. 2016; 352:i998. DOI: 10.1136/bmj.i998. View

11.

Garg S, Rodbard D, Hirsch I, Forlenza G . Managing New-Onset Type 1 Diabetes During the COVID-19 Pandemic: Challenges and Opportunities. Diabetes Technol Ther. 2020; 22(6):431-439. DOI: 10.1089/dia.2020.0161. View

12.

Bolinder J, Antuna R, Geelhoed-Duijvestijn P, Kroger J, Weitgasser R . Novel glucose-sensing technology and hypoglycaemia in type 1 diabetes: a multicentre, non-masked, randomised controlled trial. Lancet. 2016; 388(10057):2254-2263. DOI: 10.1016/S0140-6736(16)31535-5. View

13.

Zhu N, Zhang D, Wang W, Li X, Yang B, Song J . A Novel Coronavirus from Patients with Pneumonia in China, 2019. N Engl J Med. 2020; 382(8):727-733. PMC: 7092803. DOI: 10.1056/NEJMoa2001017. View

14.

Bonora B, Boscari F, Avogaro A, Bruttomesso D, Fadini G . Glycaemic Control Among People with Type 1 Diabetes During Lockdown for the SARS-CoV-2 Outbreak in Italy. Diabetes Ther. 2020; 11(6):1369-1379. PMC: 7213551. DOI: 10.1007/s13300-020-00829-7. View

15.

Gonzalez J, Tanenbaum M, Commissariat P . Psychosocial factors in medication adherence and diabetes self-management: Implications for research and practice. Am Psychol. 2016; 71(7):539-551. PMC: 5792162. DOI: 10.1037/a0040388. View

16.

Pitocco D, Tartaglione L, Viti L, Di Leo M, Manto A, Caputo S . Lack of type 1 diabetes involvement in SARS-COV-2 population: Only a particular coincidence?. Diabetes Res Clin Pract. 2020; 164:108220. PMC: 7236722. DOI: 10.1016/j.diabres.2020.108220. View

17.

Barron E, Bakhai C, Kar P, Weaver A, Bradley D, Ismail H . Associations of type 1 and type 2 diabetes with COVID-19-related mortality in England: a whole-population study. Lancet Diabetes Endocrinol. 2020; 8(10):813-822. PMC: 7426088. DOI: 10.1016/S2213-8587(20)30272-2. View

18.

Oskarsson P, Antuna R, Geelhoed-Duijvestijn P, Krger J, Weitgasser R, Bolinder J . Impact of flash glucose monitoring on hypoglycaemia in adults with type 1 diabetes managed with multiple daily injection therapy: a pre-specified subgroup analysis of the IMPACT randomised controlled trial. Diabetologia. 2017; 61(3):539-550. PMC: 6448969. DOI: 10.1007/s00125-017-4527-5. View

19.

Herzer M, Hood K . Anxiety symptoms in adolescents with type 1 diabetes: association with blood glucose monitoring and glycemic control. J Pediatr Psychol. 2009; 35(4):415-25. PMC: 2858435. DOI: 10.1093/jpepsy/jsp063. View

20.

Beato-Vibora P . RETRACTED: No deleterious effect of lockdown due to COVID-19 pandemic on glycaemic control, measured by glucose monitoring, in adults with type 1 diabetes. Diabetes Technol Ther. 2020; . DOI: 10.1089/dia.2020.0184. View